Hansoh Pharmaceutical Group CoHNSPF 90 EBITDA Margin % is 40.29% as of Dec. 2025, which is 10% above its 10-year median of 36.72. GuruFocus rates HNSPF with a GF Score™ of 90/100 and a GF Value™ of $3.00 (Modestly Overvalued). Among 954 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks better than 95.91% on this metric.
Hansoh Pharmaceutical Group Co (OTCPK:HNSPF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hansoh Pharmaceutical Group Co EBITDA Margin % Related Terms
Hansoh Pharmaceutical Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co (HNSPF) has a EBITDA Margin % of 40.29% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hansoh Pharmaceutical Group Co and its competitors. This is 10% above median its historical median of 36.72. Over the past decade, Hansoh Pharmaceutical Group Co's EBITDA Margin % has ranged from 31.96 to 46.22. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #39 out of 954 companies in the Drug Manufacturers industry, placing it in the top 4.1%.
Is Hansoh Pharmaceutical Group Co's EBITDA Margin % too high?
Hansoh Pharmaceutical Group Co's current EBITDA Margin % of 40.29% is 10% above median its 10-year median of 36.72. Over the past 10 years, this metric has ranged from a low of 31.96 to a high of 46.22. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Hansoh Pharmaceutical Group Co's value of 40.29% is 221.9% above this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #39 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #39 out of 954 companies for EBITDA Margin %. This places Hansoh Pharmaceutical Group Co in the top 4% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. Hansoh Pharmaceutical Group Co's value of 40.29% is 221.9% above this benchmark. Historically, Hansoh Pharmaceutical Group Co's own EBITDA Margin % has ranged from 31.96 to 46.22 over the past decade. While the company's 10-year median is 36.72 vs. the industry median of 12.52, Hansoh Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current EBITDA Margin % of 40.29% is 221.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current EBITDA Margin % is 40.29%, which is 10% above median its own 10-year median of 36.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.00, compared to a current price of $3.83 — trading 27.5% above its estimated fair value. The current EBITDA Margin % is 40.29%, which is 10% above median its 10-year median of 36.72 and 221.9% above the Drug Manufacturers industry median of 12.52. Hansoh Pharmaceutical Group Co's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current EBITDA Margin % is 40.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $3.83 is trading 27.5% above its estimated GF Value™ of $3.00.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for HNSPF:
EBITDA Margin %: 40.29% (10% above median its 10-year median of 36.72)
GF Value™: $3.00 vs. price of $3.83 (27.5% above fair value)
Industry Position: 221.9% above the Drug Manufacturers median (#39 of 954)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Business Description
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
90GF Score
Get the complete analysis for HNSPF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
